Biomarin Pharmaceutical Inc (BMRN)
82.17
-9.03
(-9.90%)
USD |
NASDAQ |
Apr 25, 16:00
82.20
+0.03
(+0.04%)
After-Hours: 20:00
Biomarin Pharmaceutical Revenue (Annual): 2.419B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.419B |
| December 31, 2022 | 2.096B |
| December 31, 2021 | 1.846B |
| December 31, 2020 | 1.860B |
| December 31, 2019 | 1.704B |
| December 31, 2018 | 1.491B |
| December 31, 2017 | 1.314B |
| December 31, 2016 | 1.117B |
| December 31, 2015 | 889.90M |
| December 31, 2014 | 749.28M |
| December 31, 2013 | 548.48M |
| December 31, 2012 | 500.72M |
| December 31, 2011 | 441.36M |
| Date | Value |
|---|---|
| December 31, 2010 | 376.27M |
| December 31, 2009 | 324.66M |
| December 31, 2008 | 296.49M |
| December 31, 2007 | 121.58M |
| December 31, 2006 | 84.21M |
| December 31, 2005 | 25.67M |
| December 31, 2004 | 18.64M |
| December 31, 2003 | 12.10M |
| December 31, 2002 | |
| December 31, 2001 | |
| December 31, 2000 | 9.714M |
| December 31, 1999 | 5.30M |
| December 31, 1998 | 1.20M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
1.704B
Minimum
2019
2.419B
Maximum
2023
1.985B
Average
1.860B
Median
2020
Revenue (Annual) Benchmarks
| Eli Lilly and Co | 34.12B |
| Merck & Co Inc | 60.12B |
| Pfizer Inc | 58.50B |
| Bristol-Myers Squibb Co | 45.01B |
| Moderna Inc | 6.754B |